Abstract
Programmed death-ligand 1 (PD-L1) overexpression was seen in about 40% of triple-negative advanced breast cancer (TN-ABC) patients (pts). However, PD-L1 status in HER2-negative (HER2-ve) ABC pts is poorly understood, and no biomarker related to chemotherapy (CT) for HER2-ve ABC pts excluding PD-L1 in TN-ABC has been clarified. We evaluated PD-L1 status using SP142 and explored biomarkers for first-line (1L) paclitaxel + bevacizumab (PB) therapy using immune signatures in HER2-ve ABC pts.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
